Previous 10 | Next 10 |
Advaxis (NASDAQ: ADXS ): Q1 GAAP EPS of -$0.15 beats by $0.04 . More news on: Advaxis, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
PRINCETON, N.J., March 13, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced an update on its clinical pipeline and financial results for the first quarter ...
Are These Penny Stocks On Your List This Week? With the rise of coronavirus penny stocks , speculation is driving the market right now. The key focus for novice traders is scoring a quick buck. However, emotion is a curse and a blessing especially when it comes to trading penny stocks . Fear...
First two patients treated in the combination arm who previously progressed on KEYTRUDA® showed substantial tumor shrinkage with ADXS-503 treatment in combination with KEYTRUDA® Partial response observed in one patient and the other patient achieved stable disease with a 2...
ADXS-503 safe and tolerable with potential signs of clinical activity in 4 of 7 evaluable patients achieving stable disease in the refractory setting Patient who previously progressed on pembrolizumab showed stable disease with a 25% reduction in a site lesion in combination arm PR...
Nano cap Advaxis ( ADXS -1.9% ) announces updated survival data from a Phase 1/2 clinical trial, KEYNOTE-046 , evaluating ADXS-PSA, as monotherapy and in combination with Merck's Keytruda (pembrolizumab), in patients with metastatic castration-resistant prostate cancer. The results were...
CounterPath (NASDAQ: CPAH ) +49% on securing five-year deal with Vodafone Fiji to extend superior quality voice services to consumers. More news on: CounterPath Corporation, Alpha Pro Tech, Ltd., NanoViricides, Inc., Stocks on the move, , Read more ...
Median overall survival of 16.4 months for advanced prostate cancer patients with visceral metastases treated with ADXS-PSA in combination with KEYTRUDA ® compared to an estimated 11 months with Standard of Care Median overall survival of 33.7 months in all patients treated with...
Sprint (NYSE: S ) +74% after judge approves T-Mobile merger . More news on: Sprint Corporation, Rexahn Pharmaceuticals, Inc., ZK International Group Co., Ltd., Stocks on the move, Read more ...
Advaxis (NASDAQ: ADXS ) and Personalis (NASDAQ: PSNL ) have collaborated to leverage Personalis’ ImmunoID NeXT Platform in Advaxis’ ongoing Phase 1/2 ADXS-503 (HOT Lung) program evaluating ADXS-503 alone and in combination with pembrolizumab in patients with non-small cell lu...
News, Short Squeeze, Breakout and More Instantly...
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the ...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 ...
International Zeolite Corp. (IZCFF) is expected to report for Q2 2024 International Stem Cell Corporation (ISCO) is expected to report for Q4 2023 Zivo Bioscience Inc. (ZIVO) is expected to report for Q4 2023 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4...